LIFYORLI (COPACKAGED) (Relacorilant) Patent Expiration, LOE Window & CMS Spending

LIFYORLI (COPACKAGED) (Relacorilant) by Corcept Therapeutics: FDA Orange Book core substance LOE 2041-12-22, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $37,900 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCorcept Therapeutics
FDA Application & PathwayN220641 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2041-12-22
Last Listed Patent or Exclusivity Date2041-12-22
Orange Book Patents (*PED Extensions)20 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($37,900 intro WAC)